The Clinical Investigations Support Office (CISO) serves as a centralized unit to oversee the clinical research infrastructure and assist investigators in their conduct of clinical trials and translational research projects. CISO has been reorganized following recommendations of an external advisory group and the Cancer Center Executive Committee and with the concurrence of the NCCC External Advisory Committee. The 58 personnel are now located in 15 of newly remodeled contiguous offices in the Ezralow Tower of the Cancer Center. CISO has three main operational units: 1) Protocol Administration;2) Protocol Implementation;and 3) Administrative/Business Management. The Protocol Administration Unit provides the centralized consultation and regulatory services necessary for the design, initiation, and conduct of externally-funded and internally peer-reviewed and monitored clinical trials. The Protocol Implementation Unit provides the centralized function of advising and assisting investigators in patient eligibility assessments, patient recruitment, data quality control and oversight. The Administrative/Business Management Unit was recently created in 2007 in order to coordinate CISO's relationships with institutional entities outside the Cancer Center and with sponsors. It is also charged with assisting the various investigators and sections to manage their funding sources, allocate their financial and human resources in an efficient manner, and be able to make sound projections for future growth. In addition to the services provided by the three operational units, CISO plays a central coordinating role within the Cancer Center through its interactions with other cores such as the Biostatistics Core, the Cancer Research Informatics Core (CRIC), the Translational Pathology Core, and the Protocol Review and Monitoring System entities (Clinical Investigations Committee and the Quality Assurance and Monitoring Committee). The Cancer Center Executive Committee exercises full authority over CISO policies and resource allocation and reviews the CISO's performance on a biannual basis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014089-38
Application #
8567488
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-12-01
Budget End
2013-11-30
Support Year
38
Fiscal Year
2013
Total Cost
$388,844
Indirect Cost
$141,401
Name
University of Southern California
Department
Type
DUNS #
072933393
City
Los Angeles
State
CA
Country
United States
Zip Code
90089
Gopalakrishnan, R; Matta, H; Tolani, B et al. (2016) Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors. Oncogene 35:1797-810
Zeng, Chenjie; Matsuda, Koichi; Jia, Wei-Hua et al. (2016) Identification of Susceptibility Loci and Genes for Colorectal Cancer Risk. Gastroenterology 150:1633-45
Fanini, Francesca; Fabbri, Muller (2016) Cancer-derived exosomic microRNAs shape the immune system within the tumor microenvironment: State of the art. Semin Cell Dev Biol :
Cuellar-Partida, Gabriel; Lu, Yi; Dixon, Suzanne C et al. (2016) Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Hum Genet 135:741-56
Liu, Jie; Siegmund, Kimberly D (2016) An evaluation of processing methods for HumanMethylation450 BeadChip data. BMC Genomics 17:469
Taylor, Nicholas J; Thomas, Nancy E; Anton-Culver, Hoda et al. (2016) Nevus count associations with pigmentary phenotype, histopathological melanoma characteristics and survival from melanoma. Int J Cancer 139:1217-22
Pulido, Mario A; DerHartunian, Meleeneh Kazarian; Sehgal, Prerna et al. (2016) Data on isoaspartylation of neuronal ELAVL proteins. Data Brief 9:1052-1055
Pannunzio, Nicholas R; Lieber, Michael R (2016) RNA Polymerase Collision versus DNA Structural Distortion: Twists and Turns Can Cause Break Failure. Mol Cell 62:327-34
(2016) Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Res 18:64
Van Roosbroeck, Katrien; Fanini, Francesca; Setoyama, Tetsuro et al. (2016) Combining anti-miR-155 with chemotherapy for the treatment of lung cancers. Clin Cancer Res :

Showing the most recent 10 out of 635 publications